Aptose Biosciences (APTOF) 8-K furnishes December 6, 2025 press release

Rhea-AI Filing Summary

Aptose Biosciences Inc. filed a current report to furnish information under Regulation FD. The company states that on December 6, 2025, it issued a press release, which is attached as Exhibit 99.1 to this report and incorporated by reference.

The press release is being provided under Item 7.01 (Regulation FD Disclosure) and, consistent with the stated instructions, is treated as “furnished” rather than “filed” for purposes of the Exchange Act and the Securities Act, unless later specifically incorporated by reference.

False000088236100008823612025-12-062025-12-06iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 6, 2025

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On December 6, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release dated December 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: December 6, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer

FAQ

What did Aptose Biosciences Inc. (APTOF) report in this 8-K filing?

Aptose Biosciences filed an 8-K to furnish information under Regulation FD. The report states that the company issued a press release on December 6, 2025, which is attached as Exhibit 99.1 and incorporated by reference into the current report.

What is the significance of Item 7.01 Regulation FD Disclosure for APTOF?

Item 7.01 indicates Aptose is providing information to ensure fair disclosure to all investors. The company furnished its December 6, 2025 press release under Regulation FD, clarifying that this information is not deemed “filed” for liability purposes under Section 18 of the Exchange Act.

What exhibits are included in the Aptose Biosciences (APTOF) 8-K?

The 8-K lists two exhibits: Exhibit 99.1, which is a press release dated December 6, 2025, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document, supporting electronic reporting and data accessibility requirements.

How is the December 6, 2025 press release treated in this APTOF filing?

The press release attached as Exhibit 99.1 is treated as “furnished” rather than “filed.” Aptose specifies it will not be deemed filed under Section 18 of the Exchange Act unless later expressly incorporated by reference into another Securities Act or Exchange Act filing.

Who signed the December 6, 2025 Aptose Biosciences 8-K filing?

The 8-K was signed on behalf of Aptose Biosciences Inc. by William G. Rice, Ph.D. He is identified in the document as the company’s Chairman, President, and Chief Executive Officer, confirming executive-level authorization of the current report’s contents.